Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

NCT00295854 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

296

Enrollment

INDUSTRY

Sponsor class

Conditions

Interstitial Cystitis

Interventions

DRUG: MN-001 BID
DRUG: MN-001
DRUG: Placebo

Sponsor

MediciNova